BRAIN Biotech AG - Asset Resilience Ratio
BRAIN Biotech AG (BNN) has an Asset Resilience Ratio of 9.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of BRAIN Biotech AG to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how BRAIN Biotech AG's Asset Resilience Ratio has changed over time. See debt-free asset ratio of BRAIN Biotech AG to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BRAIN Biotech AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is BRAIN Biotech AG worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.19 Million | 9.33% |
| Short-term Investments | €126.00K | 0.19% |
| Total Liquid Assets | €6.32 Million | 9.52% |
Asset Resilience Insights
- Limited Liquidity: BRAIN Biotech AG maintains only 9.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BRAIN Biotech AG Industry Peers by Asset Resilience Ratio
Compare BRAIN Biotech AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA |
Specialty Chemicals | 2.16% |
|
Air Products and Chemicals Inc
NYSE:APD |
Specialty Chemicals | 2.49% |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP |
Specialty Chemicals | 1.74% |
|
SKC Co. Ltd
KO:011790 |
Specialty Chemicals | 3.90% |
|
Shandong Dongyue Organosilicon Mat
SHE:300821 |
Specialty Chemicals | 0.00% |
|
Ningbo Shanshan Co Ltd
SHG:600884 |
Specialty Chemicals | 0.00% |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238 |
Specialty Chemicals | 40.33% |
|
5N Plus Inc.
TO:VNP |
Specialty Chemicals | 12.56% |
Annual Asset Resilience Ratio for BRAIN Biotech AG (2012–2025)
The table below shows the annual Asset Resilience Ratio data for BRAIN Biotech AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 9.52% | €6.32 Million ≈ $7.38 Million |
€66.34 Million ≈ $77.55 Million |
-21.16pp |
| 2024-09-30 | 30.69% | €27.23 Million ≈ $31.83 Million |
€88.74 Million ≈ $103.74 Million |
+23.06pp |
| 2023-09-30 | 7.62% | €5.41 Million ≈ $6.32 Million |
€70.94 Million ≈ $82.93 Million |
-3.67pp |
| 2022-09-30 | 11.29% | €8.80 Million ≈ $10.29 Million |
€77.99 Million ≈ $91.18 Million |
-20.42pp |
| 2021-09-30 | 31.71% | €24.65 Million ≈ $28.82 Million |
€77.74 Million ≈ $90.88 Million |
+5.31pp |
| 2020-09-30 | 26.40% | €19.05 Million ≈ $22.27 Million |
€72.15 Million ≈ $84.35 Million |
+3.38pp |
| 2019-09-30 | 23.02% | €15.22 Million ≈ $17.80 Million |
€66.12 Million ≈ $77.30 Million |
-11.62pp |
| 2018-09-30 | 34.65% | €25.80 Million ≈ $30.16 Million |
€74.46 Million ≈ $87.06 Million |
-22.34pp |
| 2017-09-30 | 56.99% | €39.04 Million ≈ $45.64 Million |
€68.50 Million ≈ $80.09 Million |
+17.71pp |
| 2016-09-30 | 39.28% | €18.66 Million ≈ $21.82 Million |
€47.51 Million ≈ $55.55 Million |
+38.29pp |
| 2015-09-30 | 0.99% | €299.85K ≈ $350.55K |
€30.41 Million ≈ $35.55 Million |
-6.98pp |
| 2013-09-30 | 7.97% | €2.00 Million ≈ $2.34 Million |
€25.10 Million ≈ $29.34 Million |
-13.55pp |
| 2012-09-30 | 21.52% | €4.24 Million ≈ $4.96 Million |
€19.71 Million ≈ $23.04 Million |
-- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more